News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

HemaCare (HEMA) Reports Strong First Half 2017 Results



8/21/2017 7:40:12 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB:HEMA) today reported financial results for the six months ended June 30, 2017, showing continued robust gains in revenue, gross profit, and net income compared to the same period of 2016. Revenue from operations grew 50% to $8.7 million, while gross profit of $4.5 million (52% of sales) increased by 53% compared to the same period in 2016 (51% of sales). Net income increased to $552,000, versus a prior-year loss. For complete unaudited June 30, 2017 Financial Statements, please click here.

Pete van der Wal, HemaCare’s President and Chief Executive, stated, “HemaCare continues to strengthen our leadership position as a critical supplier to customers performing cell therapy research, process development, and commercialization. Our portfolio of products and services includes leukapheresis patient collections for autologous cell therapy processing, which leads to the use of patients’ own cells to fight disease. Additionally, we provide superior leukapheresis starting material from a highly characterized, recallable donor pool, which is critical when manufacturing off-the-shelf allogeneic therapy products.”

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES